

CFML Antipodes Global

31 October 2024

Portfolio summary

The Fund's objective is to provide a total return (before the deduction of fees, charges and tax) that exceeds the return from MSCI All Country World Net Index over the investment cycle (typically 3 to 5 years).

Asset class	Equity
Style	Active
FE peer group¹	Equity - Global


Inception date	08/05/2017
Management costs	1.21% p.a.

Performance¹

	1 month (%)	3 months (%)	6 months (%)	1 year (% p.a.)	3 years (% p.a.)	5 years (% p.a.)	7 years (% p.a.)	Since inception (% p.a.)
CFML Antipodes Global	2.77	4.79	7.01	16.35	8.11	8.25	7.24	6.97
FE peer group average	2.65	1.96	7.47	24.43	7.46	10.30	10.19	10.17

Growth of \$100 since inception^{1,2}


12/05/2017 - 25/10/2024 Powered by data from FE fundinfo



Asset class breakdown³



Geographical allocation³



Top 10 holdings

For the top 10 holdings for each fund, please refer to <https://humanfinancial.com.au/performance-reports>

How the fund works

The Fund provides a diversified exposure to listed international equities through a carefully selected portfolio of investments, including both global and emerging market equities. Although currency exposure will be actively managed, the Fund's neutral exposure will be currency unhedged. The Fund will also provide exposure to short selling, both at the stock level and using index derivatives, for risk management and to add value.

When you invest your money in the Fund, your money will be pooled together with other investors' money. We use this pool to buy investments and manage them on behalf of all investors in the Fund. This means that by investing in the Fund you have access to certain investments that you may not otherwise be able to access on your own, as well as the knowledge of the skilled underlying investment managers through which the Fund may invest. ClearView Financial Management Limited (CFML) retains day-to-day control over the operation of the fund.

About the manager(s)

The CFML Antipodes Global Fund is a high conviction portfolio, typically investing in 30 to 60 assets. The manager has the discretion to utilise investments such as equity shorts and currency positions in order to take advantage of attractive risk-return opportunities and to offset specific long portfolio risks.

Antipodes Partners is a pragmatic value manager of global and emerging markets equities (long only and long-short) aspiring to grow client wealth over the long-term by generating absolute returns in excess of the benchmark at below market levels of risk. They seek to take advantage of the market's tendency for making irrational assumptions in response to changes in the operating environment, identify great businesses that are not valued as such and building high conviction portfolios with a capital preservation focus.

Antipodes Partners is majority owned by its seasoned investment team who collectively have over 100 years of global experience and significant shared history of successful investing. Their performance culture is underpinned by sensible incentives, a concentrated product offering and the outsourcing of non-investment functions to minority partner Pinnacle Investment Management to maximise their focus on investing.



Important Information

1. The FE Peer Group is the group of all funds within the relevant FE fundinfo category that each product is compared against.
2. Performance figures in this report are compiled by HFML using data from FE fundinfo. Performance may differ from HUB24 performance. Please contact HFML for further information. Performance data is after fund manager fees, but before other applicable fees or taxes and assumes the reinvestment of dividends. Past performance is not indicative of future performance. Due to the flexibility of rebalancing and variations between accounts, performance shown is indicative only and assumes rebalancing occurs at the end of each calendar month, and that there are no deposits, withdrawals nor exceptions to regular rebalancing in the model portfolio.
3. Asset class breakdown and geographic allocation may not add to 100% due to rounding and/or investment strategy.



This document has been prepared by Human Financial Management Limited (ABN 99 067 544 549, AFSL 227677) (HFML) without taking account of any individual's objectives, financial situation or needs. Investors should consider the appropriateness of this information for their circumstances, read the product disclosure statement (PDS) available at humanfinancial.com.au/pds, and obtain advice from a licensed financial adviser before making a financial decision.

The target market for each product is described in the relevant target market determination (TMD) available at humanfinancial.com.au/tmd.